What is Nutex Health's operating income?

Nutex Health's total operating income in 2025 was $275.63 million, based on the following breakdown: Total Gross Profit: $444.28 million Total Operating Expenses: $424.31 million

Nutex Health (NUTX) Financials

$204.36 -1.79 (-0.87%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$204.56 +0.20 (+0.10%)

As of 05:13 AM Eastern

Compare

Annual Income Statements for Nutex Health

This table shows Nutex Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-	-	-	-	-7.12	106	133	-425	-46	52	71
Consolidated Net Income / (Loss)	-	-	-	-	-7.12	146	169	-433	-43	95	180
Net Income / (Loss) Continuing Operations	-	-	-	-	-7.12	146	169	-433	-43	95	180
Total Pre-Tax Income	-	-	-	-	-7.12	146	169	-420	-48	110	245
Total Operating Income	-	-	-	-	-6.90	153	170	-407	-32	131	276
Total Gross Profit	-	-	-	-	0.54	158	179	15	35	196	444
Total Revenue	-	-	-	-	1.37	274	332	219	248	480	875
Operating Revenue	-	-	-	-	1.37	274	332	219	248	480	875
Total Cost of Revenue	-	-	-	-	0.83	10	106	124	123	133	175
Operating Cost of Revenue	-	-	-	-	0.83	10	106	124	123	133	175
Total Operating Expenses	-	-	-	-	7.43	110	55	502	157	216	424
Selling, General & Admin Expense	-	-	-	-	3.67	43	44	87	106	174	287
Depreciation Expense	-	-	-	-	-	5.90	7.66	13	18	19	21
Other Operating Expenses / (Income)	-	-	-	-	0.00	62	0.00	0.19	3.05	17	117
Impairment Charge	-	-	-	-	2.26	0.00	0.00	398	30	7.08	0.00
Restructuring Charge	-	-	-	-	-	0.00	3.55	3.89	0.04	0.00	0.00
Total Other Income / (Expense), net	-	-	-	-	-0.22	-7.43	-0.77	-13	-17	-21	-31
Interest Expense	-	-	-	-	0.22	6.43	6.20	12	16	20	22
Other Income / (Expense), net	-	-	-	-	-	-1.00	5.42	-0.56	-0.40	-0.94	-8.62
Income Tax Expense	-	-	-	-	-	0.18	0.97	13	-5.07	15	64
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	-	-	40	36	-7.96	2.36	43	110
Basic Earnings per Share	-	-	-	-	($1.96)	$0.18	$0.22	($100.36)	($10.39)	$10.23	$11.13
Weighted Average Basic Shares Outstanding	30.96M	39.69M	83.67M	143.68M	3.63M	4.94M	37.33M	650.93M	745.43M	5.95M	6.97M
Diluted Earnings per Share	-	-	-	-	($1.96)	$0.18	$0.22	($100.36)	($10.39)	$9.69	$10.48
Weighted Average Diluted Shares Outstanding	30.96M	39.69M	83.67M	143.68M	3.63M	4.94M	37.33M	650.93M	745.43M	5.95M	6.97M
Weighted Average Basic & Diluted Shares Outstanding	30.96M	39.69M	83.67M	143.68M	3.63M	4.94M	37.33M	650.93M	745.43M	5.95M	6.97M

This table shows Nutex Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-32	-0.36	-0.36	-8.79	62	21	-18	55	12	47	66
Consolidated Net Income / (Loss)	-28	-0.54	3.01	-7.17	100	51	16	97	17	63	96
Net Income / (Loss) Continuing Operations	-28	-0.54	3.01	-7.17	100	51	16	97	17	63	96
Total Pre-Tax Income	-31	-0.15	3.90	-2.58	109	71	24	124	26	77	117
Total Operating Income	-26	1.45	5.30	9.66	114	81	34	130	31	81	122
Total Gross Profit	13	10	23	22	142	118	125	155	46	92	141
Total Revenue	70	67	76	79	258	212	244	268	152	216	211
Operating Revenue	70	67	76	79	258	212	244	268	152	216	211
Total Cost of Revenue	32	32	32	34	35	39	41	42	53	45	48
Operating Cost of Revenue	32	32	32	34	35	39	41	42	53	45	48
Total Operating Expenses	64	34	39	35	109	92	169	95	67	90	41
Selling, General & Admin Expense	28	29	28	28	89	60	85	77	65	88	33
Depreciation Expense	4.68	4.19	4.53	4.97	5.28	5.09	5.25	5.00	5.19	5.49	5.32
Other Operating Expenses / (Income)	0.64	0.05	-0.06	1.96	15	28	79	13	-2.60	-3.92	2.88
Total Other Income / (Expense), net	-4.57	-1.60	-1.40	-12	-5.63	-9.45	-9.95	-6.43	-5.02	-4.71	-4.63
Interest Expense	4.24	4.44	5.05	5.38	5.05	6.12	5.68	5.45	4.98	4.68	4.67
Other Income / (Expense), net	-0.33	2.84	3.66	-6.86	-0.58	-3.33	-4.27	-0.98	-0.05	-0.02	0.04
Income Tax Expense	-3.00	0.39	0.89	4.59	8.61	20	7.59	27	9.29	14	21
Net Income / (Loss) Attributable to Noncontrolling Interest	3.91	-0.18	3.37	1.62	38	30	34	41	4.77	16	30
Basic Earnings per Share	($0.04)	($0.08)	($0.07)	($1.72)	$11.16	$3.74	($2.95)	$8.27	$1.70	$6.70	$9.58
Weighted Average Basic Shares Outstanding	745.43M	49.72M	5.07M	5.44M	5.53M	5.99M	-	7.07M	6.97M	6.88M	6.85M
Diluted Earnings per Share	($0.04)	($0.08)	($0.07)	($1.72)	$11.16	$3.33	($2.95)	$7.76	$1.70	$6.52	$9.38
Weighted Average Diluted Shares Outstanding	745.43M	49.72M	5.07M	5.44M	5.53M	5.99M	-	7.07M	6.97M	6.88M	6.85M
Weighted Average Basic & Diluted Shares Outstanding	745.43M	49.72M	5.07M	5.44M	5.53M	5.99M	-	7.07M	6.97M	6.88M	6.85M

This table details how cash moves in and out of Nutex Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-	-	-	-	0.95	18	11	-1.86	-12	19	145
Net Cash From Operating Activities	-	-	-	-	-4.04	87	173	51	1.26	23	248
Net Cash From Continuing Operating Activities	-	-	-	-	-4.04	87	173	51	1.26	23	248
Net Income / (Loss) Continuing Operations	-	-	-	-	-7.12	146	169	-433	-43	95	180
Consolidated Net Income / (Loss)	-	-	-	-	-7.12	146	169	-433	-43	95	180
Depreciation Expense	-	-	-	-	0.17	5.90	7.66	13	18	19	21
Non-Cash Adjustments To Reconcile Net Income	-	-	-	-	2.99	1.24	-5.51	401	34	27	118
Changes in Operating Assets and Liabilities, net	-	-	-	-	-0.08	-66	2.75	69	-7.24	-117	-71
Net Cash From Investing Activities	-	-	-	-	-0.75	-61	-37	-4.34	-11	-5.61	-5.24
Net Cash From Continuing Investing Activities	-	-	-	-	-0.75	-61	-37	-4.34	-11	-5.61	-5.24
Purchase of Property, Plant & Equipment	-	-	-	-	-0.08	-61	-37	-15	-9.50	-2.30	-2.53
Acquisitions	-	-	-	-	-0.58	0.00	0.00	-2.42	-0.70	0.00	-4.31
Purchase of Investments	-	-	-	-	-	-	-	0.00	0.00	-2.94	0.00
Sale and/or Maturity of Investments	-	-	-	-	-	-	-	-	0.00	0.00	1.60
Other Investing Activities, net	-	-	-	-	-0.10	0.00	-0.05	13	-1.04	-0.36	0.00
Net Cash From Financing Activities	-	-	-	-	5.73	-7.97	-126	-48	-2.27	1.09	-98
Net Cash From Continuing Financing Activities	-	-	-	-	5.73	-7.97	-126	-48	-2.27	1.09	-98
Repayment of Debt	-	-	-	-	-0.74	-17	-23	-7.31	-22	-17	-24
Repurchase of Common Equity	-	-	-	-	-	-	-	-	0.00	0.00	-5.00
Payment of Dividends	-	-	-	-	-	-59	-144	-	-5.22	-6.44	-74
Issuance of Debt	-	-	-	-	2.36	58	20	3.44	24	9.28	5.04
Issuance of Common Equity	-	-	-	-	4.11	-	-	0.00	0.00	9.20	0.00
Other Financing Activities, net	-	-	-	-	-	10	22	-44	0.30	5.73	0.77

This table details how cash moves in and out of Nutex Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	-4.82	8.00	11	6.10	-3.33	44	12	69	20	25	-3.53
Net Cash From Operating Activities	-1.78	3.05	13	6.79	0.05	51	27	100	70	76	34
Net Cash From Continuing Operating Activities	-1.32	3.05	13	6.79	0.05	51	27	100	70	76	34
Net Income / (Loss) Continuing Operations	-28	-0.54	3.01	-7.17	100	51	16	97	17	63	96
Consolidated Net Income / (Loss)	-28	-0.54	3.01	-7.17	100	51	16	97	17	63	96
Depreciation Expense	4.68	4.19	4.53	4.97	5.28	5.09	5.25	5.00	5.19	5.49	5.32
Non-Cash Adjustments To Reconcile Net Income	31	-1.91	4.11	9.28	63	28	75	13	-2.46	3.21	-42
Changes in Operating Assets and Liabilities, net	-9.61	1.32	1.61	-0.29	-168	-33	-69	-16	51	4.06	-26
Net Cash From Investing Activities	0.87	-0.73	-1.27	-0.27	-0.40	-0.06	0.20	-0.30	-5.07	-1.20	-2.54
Net Cash From Continuing Investing Activities	0.87	-0.73	-1.27	-0.27	-0.40	-0.06	0.20	-0.30	-5.07	-1.20	-2.54
Purchase of Property, Plant & Equipment	0.83	-0.73	-0.56	-0.62	-0.40	-0.06	-0.75	-0.30	-1.41	-1.20	-2.54
Net Cash From Financing Activities	-3.91	5.69	-1.19	-0.42	-2.99	-6.81	-15	-30	-46	-50	-35
Net Cash From Continuing Financing Activities	-3.91	5.69	-1.19	-0.42	-2.99	-6.81	-15	-30	-46	-50	-35
Repayment of Debt	-6.70	-5.95	-2.24	-3.18	-5.30	-3.47	-6.49	-7.03	-8.87	-3.70	-3.21
Repurchase of Common Equity	-	-	-	-	-	0.00	-	-	-	-32	-19
Payment of Dividends	-0.88	-0.48	-1.38	-1.80	-2.78	-7.36	-	-23	-32	-15	-13
Other Financing Activities, net	-0.35	-	0.30	1.46	3.96	0.00	8.97	0.07	0.45	1.24	0.24

This table presents Nutex Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	-	-	-	-	6.69	0.17	395	432	398	655	919
Total Current Assets	-	-	-	-	1.24	0.16	154	98	91	292	539
Cash & Equivalents	-	-	-	-	1.07	0.03	36	34	22	41	186
Restricted Cash	-	-	-	-	-	-	-	-	0.00	2.94	0.30
Accounts Receivable	-	-	-	-	0.10	0.02	115	58	63	236	325
Inventories, net	-	-	-	-	0.03	-	2.81	3.53	3.39	2.85	2.87
Prepaid Expenses	-	-	-	-	0.05	0.11	0.32	1.87	2.68	10.00	25
Plant, Property, & Equipment, net	-	-	-	-	0.00	0.01	152	82	81	78	95
Total Noncurrent Assets	-	-	-	-	5.45	0.00	89	252	226	285	285
Noncurrent Note & Lease Receivables	-	-	-	-	-	-	-	-	-	219	222
Goodwill	-	-	-	-	3.47	0.00	1.14	17	17	14	14
Intangible Assets	-	-	-	-	-	0.00	0.68	21	21	16	21
Other Noncurrent Operating Assets	-	-	-	-	1.98	0.00	87	213	188	29	28
Total Liabilities & Shareholders' Equity	-	-	-	-	6.69	0.17	395	432	398	655	919
Total Liabilities	-	-	-	-	4.83	1.30	203	311	319	467	495
Total Current Liabilities	-	-	-	-	4.61	1.15	38	55	58	154	158
Short-Term Debt	-	-	-	-	2.48	0.31	10	15	14	18	14
Accounts Payable	-	-	-	-	1.88	0.73	18	28	25	10	49
Accrued Expenses	-	-	-	-	0.03	0.00	6.86	6.24	13	25	27
Current Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	-	-	0.00	27	0.87
Current Employee Benefit Liabilities	-	-	-	-	-	-	-	-	0.00	16	8.26
Other Current Liabilities	-	-	-	-	0.05	0.00	2.94	5.92	5.90	58	59
Total Noncurrent Liabilities	-	-	-	-	0.22	0.15	165	257	261	313	337
Long-Term Debt	-	-	-	-	0.00	0.15	79	23	26	22	29
Capital Lease Obligations	-	-	-	-	-	-	66	204	214	259	269
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	0.00	0.00	10	5.15	0.00	9.09
Other Noncurrent Operating Liabilities	-	-	-	-	0.22	0.00	21	19	15	31	30
Commitments & Contingencies	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-	-	-	-	1.86	-1.13	192	120	79	189	423
Total Preferred & Common Equity	-	-	-	-	1.86	-1.13	115	96	61	132	329
Total Common Equity	-	-	-	-	1.86	-1.13	115	96	61	132	329
Common Stock	-	-	-	-	14	17	12	459	471	489	616
Retained Earnings	-	-	-	-	-13	-18	102	-363	-409	-357	-286
Noncontrolling Interest	-	-	-	-	-	0.00	77	24	18	56	94

This table presents Nutex Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	430	436	480	404	422	438	762	841	965	957	965
Total Current Assets	89	92	90	100	114	120	402	473	593	580	586
Cash & Equivalents	33	33	27	30	41	47	85	97	166	207	205
Restricted Cash	-	-	-	-	-	-	2.94	0.00	0.00	3.29	1.90
Accounts Receivable	52	52	55	66	65	66	299	355	395	346	357
Inventories, net	3.49	2.45	2.68	2.98	2.76	2.26	3.12	2.28	3.16	4.68	4.21
Prepaid Expenses	0.83	4.86	5.65	1.63	5.07	4.28	11	19	17	18	18
Plant, Property, & Equipment, net	77	83	85	81	79	78	76	83	83	95	96
Total Noncurrent Assets	264	261	304	223	230	240	284	285	289	283	283
Noncurrent Note & Lease Receivables	-	-	-	-	-	-	-	215	226	221	219
Goodwill	17	17	18	17	14	14	14	14	14	14	14
Intangible Assets	21	20	22	20	16	16	15	15	22	21	21
Other Noncurrent Operating Assets	226	224	265	186	200	211	244	28	28	27	30
Total Liabilities & Shareholders' Equity	430	436	480	404	422	438	762	841	965	957	965
Total Liabilities	321	328	375	324	340	359	507	504	526	515	457
Total Current Liabilities	48	57	67	60	72	68	196	195	185	184	117
Short-Term Debt	13	19	23	12	17	14	21	27	23	17	8.59
Accounts Payable	19	20	24	24	24	17	22	30	50	50	9.96
Accrued Expenses	10	12	15	18	23	30	25	28	28	33	31
Current Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	46	8.36	0.00	16	4.01
Current Employee Benefit Liabilities	-	-	-	-	-	-	21	24	11	2.72	4.85
Other Current Liabilities	5.61	5.66	5.73	5.95	7.57	7.32	62	78	74	66	59
Total Noncurrent Liabilities	273	271	307	264	269	291	310	309	341	331	340
Long-Term Debt	25	25	19	26	22	27	22	20	26	24	31
Capital Lease Obligations	221	-	264	213	227	241	258	258	270	269	269
Noncurrent Deferred & Payable Income Tax Liabilities	9.54	8.73	8.49	5.05	2.80	3.40	-	-	15	8.16	11
Other Noncurrent Operating Liabilities	17	237	16	20	17	20	30	31	30	30	29
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	110	108	105	80	82	80	255	337	438	442	507
Total Preferred & Common Equity	93	93	90	63	63	60	177	235	317	346	394
Total Common Equity	93	93	90	63	63	60	177	235	317	346	394
Common Stock	461	465	467	472	473	479	513	589	615	586	568
Retained Earnings	-368	-372	-377	-409	-410	-419	-336	-353	-298	-239	-174
Noncontrolling Interest	17	16	15	17	19	19	78	102	121	96	113

This table displays calculated financial ratios and metrics derived from Nutex Health's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	39,683,990.00	39,683,990.00	124,393,746.00	181,639,817.00	4,627,721.00	5,262,910.00	48,027,683.00	-	-	-	14,143,832.00
DEI Adjusted Shares Outstanding	264,560.00	264,560.00	829,292.00	1,210,932.00	30,851.00	35,086.00	320,185.00	-	-	-	14,143,832.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-230.67	3,020.29	414.11	-	-	-	5.00
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	0.00	0.00	0.00	0.00	-4.83	153	169	-285	-22	113	203
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-78.59%	-6.67%	22.60%	27.61%
Earnings before Interest and Taxes (EBIT)	0.00	0.00	0.00	0.00	-6.90	152	176	-407	-32	130	267
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.00	0.00	0.00	0.00	-6.73	158	183	-394	-15	149	288
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.00	0.00	0.00	-8.10	157	-142	-302	-5.81	-33	98
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	0.00	0.00	0.00	3.27	-0.70	310	328	311	458	550
Increase / (Decrease) in Invested Capital	0.00	0.00	0.00	0.00	3.27	-3.97	311	18	-16	147	105
Book Value per Share	$0.00	$0.00	$0.00	$0.00	$0.40	($0.22)	$2.39	$0.15	$0.09	$26.92	$46.59
Tangible Book Value per Share	$0.00	$0.00	$0.00	$0.00	($0.35)	($0.22)	$2.35	$0.09	$0.04	$21.50	$41.62
Total Capital	0.00	0.00	0.00	0.00	4.34	-0.67	346	362	333	502	736
Total Debt	0.00	0.00	0.00	0.00	2.48	0.46	155	242	254	300	312
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.15	145	227	240	282	298
Net Debt	0.00	0.00	0.00	0.00	1.41	0.44	119	208	232	256	126
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.08	61	37	15	9.50	2.30	2.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	0.00	0.00	0.00	-1.95	-0.71	90	24	25	126	209
Debt-free Net Working Capital (DFNWC)	0.00	0.00	0.00	0.00	-0.89	-0.68	127	58	47	170	395
Net Working Capital (NWC)	0.00	0.00	0.00	0.00	-3.37	-1.00	116	43	33	152	381
Net Nonoperating Expense (NNE)	0.00	0.00	0.00	0.00	2.29	7.43	0.77	148	21	18	23
Net Nonoperating Obligations (NNO)	0.00	0.00	0.00	0.00	1.41	0.44	119	208	232	256	126
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.17	5.90	7.66	13	18	19	21
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($28.50)	$1.50	($3.00)	($294.00)	($171.00)	($55.50)	($100.50)	($10.50)	$10.25	$11.13
Adjusted Weighted Average Basic Shares Outstanding	206.42K	264.59K	557.81K	957.89K	24.20K	261.67K	322.97K	4.34M	4.97M	5.53M	6.97M
Adjusted Diluted Earnings per Share	$0.00	($28.50)	$1.50	($3.00)	($294.00)	($171.00)	($55.50)	($100.50)	($10.50)	$9.71	$10.48
Adjusted Weighted Average Diluted Shares Outstanding	194.46K	264.59K	557.81K	957.89K	24.20K	261.67K	322.97K	4.34M	4.97M	5.53M	6.97M
Adjusted Basic & Diluted Earnings per Share	$0.00	($28.50)	$1.50	($3.00)	($294.00)	($171.00)	($55.50)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	206.42K	264.59K	557.81K	957.89K	24.20K	32.95K	248.83K	4.34M	4.97M	5.53M	6.97M
Normalized Net Operating Profit after Tax (NOPAT)	0.00	0.00	0.00	0.00	-3.25	153	173	-3.20	-1.06	120	203
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Nutex Health's official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	-	-	-	-	-	11,478,987.00	11,553,449.00	11,553,449.00	14,143,832.00	6,968,350.00	6,881,339.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	11,478,987.00	11,553,449.00	11,553,449.00	14,143,832.00	6,968,350.00	6,881,339.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	1.85	-1.53	4.80	0.84	6.72	9.57
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	29.68%	19.75%	29.12%	25.62%	269.77%	213.98%	220.69%	239.87%	-	2.22%	-13.62%
EBITDA Growth	-701.28%	1,325.01%	243.28%	95.40%	645.70%	872.26%	156.90%	1,628.98%	-	5.22%	266.65%
EBIT Growth	-341.86%	191.45%	3,848.23%	464.65%	529.22%	1,701.86%	228.31%	4,519.46%	-	5.05%	314.00%
NOPAT Growth	-352.42%	132.61%	1,709.99%	1,276.62%	674.57%	5,569.37%	460.77%	1,405.29%	-	15.77%	337.04%
Net Income Growth	-159.99%	92.16%	170.56%	-58.38%	460.75%	9,473.80%	436.35%	1,451.00%	-	23.53%	496.61%
EPS Growth	-159.99%	92.16%	170.56%	-37.60%	28,000.00%	4,262.50%	-4,114.29%	551.16%	-	95.80%	417.97%
Operating Cash Flow Growth	-139.42%	190.00%	107,538.69%	244.93%	103.01%	1,570.44%	105.56%	1,366.03%	-	48.18%	25.47%
Free Cash Flow Firm Growth	91.37%	113.10%	-129.71%	244.41%	-2,117.77%	-404.39%	-17.12%	-328.37%	-	94.32%	117.10%
Invested Capital Growth	-5.01%	-10.40%	156.37%	-18.14%	47.10%	55.46%	77.33%	87.91%	-	15.55%	11.62%
Revenue Q/Q Growth	11.07%	-3.18%	12.79%	3.57%	226.95%	-17.79%	15.20%	9.76%	-	42.73%	-2.65%
EBITDA Q/Q Growth	-647.79%	138.91%	59.14%	-42.39%	1,429.78%	-30.73%	-57.95%	287.77%	-	140.55%	46.51%
EBIT Q/Q Growth	-3,346.96%	116.21%	108.75%	-68.74%	3,957.42%	-31.99%	-61.97%	339.96%	-	163.17%	49.87%
NOPAT Q/Q Growth	-3,083.64%	105.54%	302.65%	65.55%	1,454.63%	-45.02%	-60.19%	344.42%	-	235.95%	50.30%
Net Income Q/Q Growth	-512.55%	98.04%	654.89%	-338.02%	1,495.24%	-48.94%	-68.22%	499.60%	-	277.91%	53.46%
EPS Q/Q Growth	-512.55%	98.04%	654.89%	-2,357.14%	748.84%	-67.83%	-188.59%	363.05%	-	283.53%	43.87%
Operating Cash Flow Q/Q Growth	-190.24%	271.76%	334.63%	-48.80%	-99.21%	95,229.39%	-46.52%	265.10%	-	7.29%	-54.71%
Free Cash Flow Firm Q/Q Growth	96.46%	2,020.92%	-609.74%	141.67%	-154.35%	-281.84%	-96.14%	18.75%	-	92.67%	689.93%
Invested Capital Q/Q Growth	-18.92%	-3.26%	2.07%	2.24%	45.70%	5.31%	16.43%	8.35%	-	-1.52%	12.47%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	18.97%	15.06%	29.65%	27.82%	54.98%	55.88%	51.20%	57.83%	-	42.37%	67.04%
EBITDA Margin	-31.28%	12.57%	17.73%	9.86%	46.16%	38.92%	14.21%	50.18%	-	40.06%	60.30%
Operating Margin	-37.53%	2.15%	6.96%	12.26%	44.33%	38.09%	13.80%	48.68%	-	37.54%	57.75%
EBIT Margin	-38.00%	6.36%	11.78%	3.55%	44.11%	36.52%	12.05%	48.32%	-	37.53%	57.77%
Profit (Net Income) Margin	-39.78%	-0.80%	3.96%	-9.09%	38.81%	23.99%	6.62%	36.15%	-	28.99%	45.70%
Tax Burden Percent	90.24%	354.98%	77.10%	277.66%	92.07%	71.34%	68.03%	78.10%	-	81.98%	82.26%
Interest Burden Percent	116.00%	-3.56%	43.58%	-92.14%	95.55%	92.09%	80.69%	95.79%	-	94.24%	96.16%
Effective Tax Rate	0.00%	0.00%	22.90%	0.00%	7.93%	28.66%	31.97%	21.90%	-	18.02%	17.74%
Return on Invested Capital (ROIC)	-20.35%	1.22%	6.93%	7.18%	50.90%	44.07%	17.44%	82.40%	-	53.63%	69.70%
ROIC Less NNEP Spread (ROIC-NNEP)	-24.63%	0.53%	6.03%	1.76%	48.78%	40.97%	14.32%	79.81%	-	51.16%	67.25%
Return on Net Nonoperating Assets (RNNOA)	-54.33%	1.24%	7.52%	4.89%	84.84%	53.10%	14.84%	59.75%	-	22.93%	24.70%
Return on Equity (ROE)	-74.68%	2.46%	14.45%	12.06%	135.74%	97.16%	32.29%	142.15%	-	76.56%	94.40%
Cash Return on Invested Capital (CROIC)	-1.82%	5.29%	-94.38%	18.00%	-8.66%	0.57%	-11.50%	2.67%	-	27.64%	39.09%
Operating Return on Assets (OROA)	-22.68%	3.95%	7.57%	2.26%	40.19%	39.09%	15.12%	67.58%	-	38.42%	54.18%
Return on Assets (ROA)	-23.74%	-0.50%	2.54%	-5.78%	35.36%	25.68%	8.30%	50.56%	-	29.68%	42.86%
Return on Common Equity (ROCE)	-58.91%	2.02%	11.80%	9.82%	100.38%	69.54%	22.97%	103.66%	-	57.45%	70.40%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-58.78%	-47.45%	-53.62%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-18	1.01	4.09	6.76	105	58	23	102	20	67	100
NOPAT Margin	-26.27%	1.50%	5.37%	8.58%	40.82%	27.17%	9.39%	38.02%	-	30.77%	47.51%
Net Nonoperating Expense Percent (NNEP)	4.28%	0.70%	0.91%	5.42%	2.12%	3.10%	3.12%	2.59%	-	2.47%	2.46%
Return On Investment Capital (ROIC_SIMPLE)	-5.49%	-	-	-	20.96%	10.35%	3.57%	13.45%	2.70%	8.86%	12.27%
Cost of Revenue to Revenue	46.23%	47.92%	42.04%	42.94%	13.46%	18.25%	16.84%	15.73%	-	20.99%	22.82%
SG&A Expenses to Revenue	40.28%	43.65%	36.35%	35.46%	34.47%	28.20%	34.93%	28.79%	-	40.74%	15.53%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Operating Expenses to Revenue	91.29%	49.93%	50.99%	44.80%	42.21%	43.66%	69.35%	35.59%	-	41.47%	19.43%
Earnings before Interest and Taxes (EBIT)	-26	4.29	8.96	2.80	114	77	29	129	31	81	122
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-22	8.48	13	7.77	119	82	35	134	36	87	127
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.96	1.13	0.47	1.82	1.18	1.47	2.95	1.81	-	1.91	2.98
Price to Tangible Book Value (P/TBV)	5.06	2.77	0.91	3.58	1.47	1.76	3.36	2.04	-	2.13	3.27
Price to Revenue (P/Rev)	0.49	0.28	0.11	0.38	0.36	0.42	0.87	0.59	-	0.75	1.39
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	3.30	3.53	12.30	4.77	-	6.87	6.54
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	30.28%	28.34%	8.13%	20.97%	-	14.55%	15.30%
Enterprise Value to Invested Capital (EV/IC)	1.19	1.03	0.89	1.16	1.06	1.18	1.84	1.44	-	1.58	2.28
Enterprise Value to Revenue (EV/Rev)	1.50	1.20	0.99	1.25	1.01	0.88	1.27	0.87	-	0.97	1.64
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	66.02	45.77	3.26	2.48	4.11	2.29	-	2.94	3.62
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	3.73	2.72	4.49	2.43	-	3.16	3.83
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	4.27	3.26	5.31	2.94	-	4.04	4.81
Enterprise Value to Operating Cash Flow (EV/OCF)	295.10	95.17	16.63	17.07	20.91	7.76	11.79	4.77	-	3.14	4.97
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	18.36	0.00	5.79	0.00	252.55	0.00	70.35	-	6.14	6.16
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.22	3.14	3.25	3.53	1.49	1.18	0.91	0.73	-	0.70	0.61
Long-Term Debt to Equity	3.04	2.99	3.04	3.36	1.40	1.10	0.83	0.68	-	0.66	0.59
Financial Leverage	2.21	2.36	1.25	2.78	1.74	1.30	1.04	0.75	-	0.45	0.37
Leverage Ratio	4.16	4.40	4.51	4.97	3.75	3.48	3.02	2.71	-	2.47	2.14
Compound Leverage Factor	4.83	-0.16	1.97	-4.58	3.58	3.20	2.43	2.60	-	2.32	2.06
Debt to Total Capital	76.28%	75.85%	76.46%	77.92%	59.77%	54.10%	47.54%	42.14%	-	41.21%	37.82%
Short-Term Debt to Total Capital	4.25%	3.67%	4.92%	3.84%	3.58%	3.73%	4.18%	3.08%	-	2.24%	1.05%
Long-Term Debt to Total Capital	72.03%	72.18%	71.54%	74.08%	56.19%	50.37%	43.37%	39.06%	-	38.97%	36.77%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Noncontrolling Interests to Total Capital	5.29%	5.13%	5.54%	5.35%	11.07%	14.08%	15.83%	15.97%	-	12.73%	13.85%
Common Equity to Total Capital	18.43%	19.02%	18.01%	16.72%	29.16%	31.82%	36.63%	41.90%	-	46.05%	48.33%
Debt to EBITDA	-17.45	-46.50	64.08	35.42	2.02	1.35	1.25	0.86	-	1.06	0.80
Net Debt to EBITDA	-15.94	-40.95	54.27	29.52	1.72	0.96	0.86	0.41	-	0.34	0.26
Long-Term Debt to EBITDA	-16.47	-44.25	59.96	33.67	1.90	1.26	1.14	0.80	-	1.00	0.78
Debt to NOPAT	-11.44	-13.87	-18.82	-41.33	2.64	1.78	1.62	1.11	-	1.46	1.07
Net Debt to NOPAT	-10.45	-12.22	-15.94	-34.45	2.26	1.26	1.10	0.53	-	0.47	0.35
Long-Term Debt to NOPAT	-10.80	-13.20	-17.61	-39.29	2.49	1.65	1.47	1.02	-	1.38	1.04
Altman Z-Score	-0.71	-0.49	-0.46	-0.32	1.05	1.17	1.69	2.19	-	2.12	3.17
Noncontrolling Interest Sharing Ratio	21.12%	17.89%	18.34%	18.58%	26.05%	28.43%	28.87%	27.08%	-	24.96%	25.42%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.56	1.68	1.59	1.77	2.08	2.05	2.43	3.20	-	3.14	5.00
Quick Ratio	1.45	1.60	1.48	1.68	1.99	1.96	2.32	3.02	-	3.00	4.79
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1.87	36	-184	76	-42	-110	-215	-175	-85	-6.23	37
Operating Cash Flow to CapEx	0.00%	416.03%	2,375.63%	1,100.12%	13.53%	79,632.81%	3,629.43%	32,951.66%	-	6,287.93%	1,346.46%
Free Cash Flow to Firm to Interest Expense	-0.44	8.10	-36.31	14.21	-8.23	-17.91	-37.86	-32.03	-	-1.33	7.87
Operating Cash Flow to Interest Expense	-0.42	0.69	2.62	1.26	0.01	8.33	4.80	18.25	-	16.13	7.32
Operating Cash Flow Less CapEx to Interest Expense	-0.22	0.52	2.51	1.15	-0.07	8.32	4.67	18.20	-	15.87	6.78
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.60	0.62	0.64	0.64	0.91	1.07	1.25	1.40	-	1.02	0.94
Accounts Receivable Turnover	4.09	4.41	4.71	4.82	3.21	3.42	3.77	4.26	-	2.73	2.38
Inventory Turnover	35.39	38.69	49.46	52.75	42.57	45.67	58.90	57.80	-	46.71	58.35
Fixed Asset Turnover	3.03	3.28	3.41	3.57	6.02	7.95	9.79	12.18	-	10.27	9.48
Accounts Payable Turnover	4.64	5.81	5.87	6.45	7.61	6.04	5.53	4.73	-	5.03	9.45
Days Sales Outstanding (DSO)	89.24	82.70	77.55	75.65	113.63	106.73	96.80	85.77	-	133.82	153.39
Days Inventory Outstanding (DIO)	10.31	9.43	7.38	6.92	8.58	7.99	6.20	6.32	-	7.81	6.26
Days Payable Outstanding (DPO)	78.66	62.85	62.15	56.57	47.95	60.40	65.97	77.20	-	72.50	38.61
Cash Conversion Cycle (CCC)	20.89	29.28	22.78	26.00	74.25	54.32	37.03	14.88	-	69.13	121.03
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	311	301	308	314	458	468	545	591	550	541	609
Invested Capital Turnover	0.77	0.81	1.29	0.84	1.25	1.62	1.86	2.17	-	1.74	1.47
Increase / (Decrease) in Invested Capital	-16	-35	188	-70	147	167	238	276	105	73	63
Enterprise Value (EV)	371	310	274	364	484	552	1,003	849	-	857	1,390
Market Capitalization	121	71	30	110	172	260	693	575	-	662	1,176
Book Value per Share	$0.09	$0.08	$1.26	$11.93	$26.92	$32.55	$42.27	$56.99	$46.59	$49.70	$57.30
Tangible Book Value per Share	$0.04	$0.03	$0.66	$6.05	$21.50	$27.19	$37.09	$50.61	$41.62	$44.70	$52.29
Total Capital	333	331	348	361	502	556	642	757	736	752	816
Total Debt	254	251	266	282	300	301	305	319	312	310	309
Total Long-Term Debt	240	239	249	268	282	280	278	296	298	293	300
Net Debt	232	221	226	235	256	213	209	153	126	99	101
Capital Expenditures (CapEx)	-0.83	0.73	0.56	0.62	0.40	0.06	0.75	0.30	1.41	1.20	2.54
Debt-free, Cash-free Net Working Capital (DFCFNWC)	25	23	19	19	126	138	208	264	209	201	270
Debt-free Net Working Capital (DFNWC)	47	53	59	66	170	226	305	431	395	412	477
Net Working Capital (NWC)	33	40	42	52	152	205	278	407	381	395	468
Net Nonoperating Expense (NNE)	9.41	1.56	1.08	14	5.18	6.74	6.77	5.02	3.22	3.86	3.81
Net Nonoperating Obligations (NNO)	232	221	226	235	256	213	209	153	126	99	101
Total Depreciation and Amortization (D&A)	4.68	4.19	4.53	4.97	5.28	5.09	5.25	5.00	5.19	5.49	5.32
Debt-free, Cash-free Net Working Capital to Revenue	9.98%	8.74%	6.72%	6.58%	26.25%	22.17%	26.29%	26.95%	-	22.89%	31.88%
Debt-free Net Working Capital to Revenue	18.86%	20.34%	21.51%	22.64%	35.33%	36.22%	38.50%	43.88%	-	46.83%	56.34%
Net Working Capital to Revenue	13.14%	15.64%	15.30%	17.89%	31.59%	32.89%	35.11%	41.50%	-	44.91%	55.32%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($6.00)	($0.10)	($0.07)	($1.72)	$11.16	$3.74	($2.95)	$8.27	$1.70	$6.70	$9.58
Adjusted Weighted Average Basic Shares Outstanding	4.97M	4.97M	5.07M	5.44M	5.53M	5.99M	0.00	7.07M	6.97M	6.88M	6.85M
Adjusted Diluted Earnings per Share	($6.00)	($0.10)	($0.07)	($1.72)	$11.16	$3.33	($2.95)	$7.76	$1.70	$6.52	$9.38
Adjusted Weighted Average Diluted Shares Outstanding	4.97M	4.97M	5.07M	5.44M	5.53M	5.99M	0.00	7.07M	6.97M	6.88M	6.85M
Adjusted Basic & Diluted Earnings per Share	($6.00)	$0.00	$0.00	$0.00	$11.16	$0.00	$0.00	$0.00	$1.70	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	4.97M	4.97M	5.07M	5.44M	5.53M	5.99M	0.00	7.07M	6.97M	6.88M	6.85M
Normalized Net Operating Profit after Tax (NOPAT)	-18	1.01	9.23	7.06	105	58	23	102	20	67	100
Normalized NOPAT Margin	-26.27%	1.50%	12.13%	8.96%	40.82%	27.17%	9.39%	38.02%	-	30.77%	47.51%
Pre Tax Income Margin	-44.08%	-0.23%	5.13%	-3.27%	42.15%	33.63%	9.73%	46.28%	-	35.37%	55.56%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-6.25	0.97	1.77	0.52	22.49	12.64	5.18	23.73	-	17.35	26.07
NOPAT to Interest Expense	-4.32	0.23	0.81	1.26	20.81	9.40	4.04	18.68	-	14.23	21.44
EBIT Less CapEx to Interest Expense	-6.05	0.80	1.66	0.41	22.41	12.63	5.05	23.68	-	17.10	25.52
NOPAT Less CapEx to Interest Expense	-4.13	0.06	0.70	1.14	20.74	9.39	3.90	18.62	-	13.97	20.89
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-12.01%	-11.23%	-14.75%	-14.00%	6.76%	0.00%	0.00%	0.00%	-	42.78%	30.87%
Augmented Payout Ratio	-12.01%	-11.23%	-14.75%	-14.00%	6.76%	0.00%	0.00%	0.00%	-	61.88%	51.31%

Financials Breakdown Chart

Key Financial Trends

Nutex Health’s financial profile has improved substantially from 2022 and early 2023 levels. Revenue increased from approximately $28.4 million in Q3 2022 to $210.8 million in Q2 2026, although the growth path has been uneven. After reaching $267.8 million in Q3 2025, revenue declined to $151.7 million in Q4 2025 before recovering above $200 million in the first half of 2026.

Profitability is currently a major strength. Q2 2026 gross profit was $141.3 million, representing a gross margin of approximately 67%. Operating income reached $121.7 million, compared with $81.3 million in Q1 2026 and $30.9 million in Q4 2025. Net income attributable to common shareholders rose to $65.8 million, or $9.58 per basic share, versus $46.8 million, or $6.70 per share, in Q1. The company has moved from recurring losses in 2022 and 2023 to consistently positive earnings in the more recent quarters.

Cash generation has also been positive, though somewhat volatile. Operating cash flow was $34.2 million in Q2 2026 and $75.5 million in Q1 2026, following $70.4 million in Q4 2025 and $99.5 million in Q3 2025. The company ended Q2 with $205.2 million of cash and equivalents, supported by $34.2 million of operating cash flow despite significant shareholder distributions and debt repayments.

Strong earnings recovery: Q2 2026 net income attributable to common shareholders increased approximately 41% sequentially from Q1 2026 and was substantially higher than the $11.8 million recorded in Q4 2025.
Significant margin expansion: Q2 2026 operating margin was approximately 57.7%, compared with 37.5% in Q1 2026 and 20.4% in Q4 2025.
Improved liquidity: Cash and equivalents of $205.2 million and current assets of $585.7 million compared with current liabilities of $117.2 million, producing a current ratio near 5.0.
Balance-sheet equity has strengthened: Total common equity increased to $394.3 million in Q2 2026 from $63.0 million in Q1 2024, while the accumulated retained-earnings deficit narrowed materially to $173.5 million.
Revenue remains volatile: Revenue has grown dramatically over the longer term, but the decline from $267.8 million in Q3 2025 to $151.7 million in Q4 2025 shows that quarterly results may be affected by changing business mix, acquisitions or other nonrecurring factors.
Cash flow is sensitive to working capital: Changes in operating assets and liabilities reduced Q2 2026 operating cash flow by $25.6 million, following a $4.1 million benefit in Q1. This suggests that reported earnings do not always translate into cash at the same rate.
Large lease obligations remain: Capital lease obligations totaled $268.9 million at Q2 2026, representing the majority of the company’s $340.1 million of noncurrent liabilities and creating long-term fixed payment obligations.
Receivables are elevated: Accounts receivable reached $356.7 million, or roughly 61% of current assets. Investors should monitor collections and potential credit losses because slower collections could pressure future cash flow.
Financing outflows are substantial: Q2 2026 financing cash flow was negative $35.2 million after $18.9 million of share repurchases, $13.3 million of dividends and $3.2 million of debt repayments. These distributions exceeded operating cash flow during the quarter and reduced cash by $3.5 million overall.
Noncontrolling interests reduce common-stockholder participation: Q2 2026 consolidated net income was $96.3 million, but $30.5 million was attributable to noncontrolling interests. Investors therefore receive only a portion of the consolidated earnings generated by the company’s operations.

Overall, Nutex Health’s statements show a much stronger operating and liquidity position than the loss-making period in 2022 and 2023. However, the investment case still depends on whether recent margins and earnings can be sustained, whether large receivable balances convert into cash, and whether lease obligations and shareholder distributions limit financial flexibility.

10/14/26 06:51 AM ETAI Generated. May Contain Errors.

Nutex Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Nutex Health's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Nutex Health's net income appears to be on an upward trend, with a most recent value of $180.36 million in 2025, rising from $0.00 in 2015. The previous period was $94.81 million in 2024. See where experts think Nutex Health is headed by visiting Nutex Health's forecast page.

Nutex Health's total operating income in 2025 was $275.63 million, based on the following breakdown:

Total Gross Profit: $444.28 million
Total Operating Expenses: $424.31 million

Over the last 10 years, Nutex Health's total revenue changed from $0.00 in 2015 to $875.26 million in 2025, a change of 87,525,700,000.0%.

In the past 13 quarters, Nutex Health's cash and equivalents has ranged from $26.83 million in Q3 2023 to $207.35 million in Q1 2026, and is currently $205.21 million as of their latest financial filing in Q2 2026.

Nutex Health had total debt of $312.13 million at the end of 2025, a 4.1% increase from 2024, and none in 2015.

Over the last 10 years, Nutex Health's book value per share changed from 0.00 in 2015 to 46.59 in 2025, a change of 4,658.5%.

Related Companies

Financial statements for NASDAQ:NUTX last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nutex Health (NUTX) Financials

Financials Breakdown Chart

Key Financial Trends

Nutex Health Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nutex Health (NUTX) Financials

Annual Income Statements for Nutex Health

Quarterly Income Statements for Nutex Health

Annual Cash Flow Statements for Nutex Health

Quarterly Cash Flow Statements for Nutex Health

Annual Balance Sheets for Nutex Health

Quarterly Balance Sheets for Nutex Health

Annual Metrics And Ratios for Nutex Health

Quarterly Metrics And Ratios for Nutex Health

Financials Breakdown Chart

Key Financial Trends

Nutex Health Financials - Frequently Asked Questions

When does Nutex Health's fiscal year end?

How has Nutex Health's net income changed over the last 10 years?

What is Nutex Health's operating income?

How has Nutex Health's revenue changed over the last 10 years?

How much cash does Nutex Health have?

How much debt does Nutex Health have?

How has Nutex Health's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools